ONGOING measles outbreaks indicate severe clinical infection risks for vulnerable adults living with autoimmune rheumatic diseases. As pediatric vaccination rates decline, measles resurgence poses an immediate threat to immunocompromised patients who cannot mount robust defense mechanisms independently. Halting community transmission of this highly contagious virus requires a herd immunity threshold of approximately 95%. When population coverage dips below this protective benchmark, individuals with autoimmune conditions face heightened exposure hazards driven by underlying immune dysregulation and ongoing immunosuppressive drug regimens.
For adults with autoimmune rheumatic diseases, clinical management demands rigorous evaluation of measles immunity. The measles, mumps, and rubella vaccine contains a live-attenuated virus that effectively primes immunocompetent immune systems through a two-dose series administered at least four weeks apart. However, administering live measles formulations remains strictly contraindicated in patients actively taking conventional synthetic, targeted synthetic, or biologic disease-modifying antirheumatic drugs. Because live-attenuated viral strains generate viremia that may persist for up to four weeks in immunosuppressed individuals, administering the vaccine during active treatment introduces substantial risks of vaccine-strain infection.
When unimmunized patients require measles protection, clinicians must implement tailored therapy interruptions before immunization. Current clinical guidelines recommend withholding methotrexate, leflunomide, and systemic glucocorticoids for four weeks prior to administering the measles vaccine. Targeted synthetic options such as Janus kinase inhibitors require a one-week pause, whereas B cell-depleting agents like rituximab necessitate a six-month delay. Other biologics require suspension for one dosing interval. Following measles immunization, all antirheumatic treatments must be withheld for an additional four weeks to ensure complete viral clearance. Promisingly, recent trials investigating CD19-directed chimeric antigen receptor T cell therapy in refractory autoimmune diseases showed preserved antibody titers against measles following cellular treatment. Clinicians must balance infection risks with flare prevention to shield susceptible populations effectively.
Reference
Kapetanovic MC. Vaccination considerations in autoimmune rheumatic diseases. Nat Rev Rheumatol. 2026
Featured Image: Leigh Prather on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
